Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?,

Lale Kostakoglu, MD, MPH, Heiko Schoder, MD, Nathan Hall, MD, PhD, David J. Straus, MD, Jeffrey L Johnson, PhD, Lawrence Schwartz, MD, Ann LaCasce, MD, Sin-Ho Jung, PhD, Nancy L. Bartlett, MD, George P. Canellos, MD, Bruce D. Cheson, MD

Blood (2011) 118 (21): 3644.

https://doi.org/10.1182/blood.V118.21.3644.3644

Published: 2011

Journal Articles

Early Interim FDG-PET Scan Predicts Outcome in Non-Bulky Limited Stage Hodgkin Lymphoma, but may Not Guide Use of Consolidative Radiotherapy.

Jeffrey A. Barnes, M.D., Ann S. LaCasce, MD, Christiana E. Toomey, Ephraim Hochberg, Alfred I. Lee, George P. Canellos, MD, Jeremy S. Abramson, MD

Blood (2008) 112 (11): 1453.

https://doi.org/10.1182/blood.V112.11.1453.1453

Published: 2008

Journal Articles

Chemotherapy Alone for Localized Non-Bulky Hodgkin Lymphoma

George P. Canellos, MD

Blood (2008) 112 (11): 2591.

https://doi.org/10.1182/blood.V112.11.2591.2591

Published: 2008

Journal Articles

Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results.

Lale Kostakoglu, MD, MPH, David J. Straus, MD, Heiko Schöder, MD, Ann S. LaCasce, MD, Nancy L Bartlett, MD, Nathan Hall, MD, PhD, Jeffrey L Johnson, PhD, Sin-Ho Jung, PhD, George P. Canellos, MD, Lawrence H Schwartz, MD, Bruce D. Cheson, MD

Blood (2008) 112 (11): 1460.

https://doi.org/10.1182/blood.V112.11.1460.1460

Published: 2008

Journal Articles

Non-Myeloablative Allogeneic Transplantation for Hodgkin’s and Non-Hodgkin’s Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism.

Philippe Armand, MD, PhD, Haesook T. Kim, PhD, Ann S. LaCasce, MD, Corey S. Cutler, MD, Vincent T. Ho, MD, John Koreth, MD, Eric D. Jacobsen, MD, David C. Fisher, MD, Jennifer R. Brown, MD, George P. Canellos, MD, Joseph H. Antin, MD, Arnold S. Freedman, MD, Robert J. Soiffer, MD, Edwin P. Alyea, MD

Blood (2007) 110 (11): 3041.

https://doi.org/10.1182/blood.V110.11.3041.3041

Published: 2007

Journal Articles

Immuno-Chemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909.

Lloyd E. Damon, MD, Jeff Johnson, Donna Niedzwiecki, Bruce D. Cheson, MD, David Duane Hurd, MD, Nancy L. Bartlett, MD, John C. Byrd, Michael Kelly, Charles Linker, MD, George P. Canellos, MD

Blood (2006) 108 (11): 2737.

https://doi.org/10.1182/blood.V108.11.2737.2737

Published: 2006

Journal Articles

CALGB 59901: Results of a Phase II Study of 506U78 in CTCL and PTCL.

Myron S. Czuczman, MD, Pierluigi Porcu, MD, Jeff Johnson, Donna Niedzwiecki, George P. Canellos, MD, Bruce D. Cheson, MD

Blood (2004) 104 (11): 2486.

https://doi.org/10.1182/blood.V104.11.2486.2486

Published: 2004

Journal Articles

Sequential Topoisomerase I (Topo I) and Topoisomerase II (Topo II) Inhibitors in Relapsed/Refractory Aggressive NHL: Results of CALGN 59906, a Phase II Study of Doxorubicin and Topotecan.

Sonali M. Smith, MD, Jeffrey L. Johnson, MS, Donna Niedzwiecki, PhD, J. Paul Eder, MD, George P. Canellos, MD, Bruce D. Cheson, MD, Nancy L. Bartlett, MD

Blood (2004) 104 (11): 2500.

https://doi.org/10.1182/blood.V104.11.2500.2500

Published: 2004

Journal Articles

Eradication of Minimal Residual Disease during Treatment of Mantle Cell Lymphoma: CALGB 59909.

Dorie Sher, BS, Jeffrey Johnson, PhD, Mariah Siddiqui, Michael A. Caligiuri, MD, Lloyd E. Damon, MD, George P. Canellos, MD, Charles Linker, MD, Bruce D. Cheson, MD, Wendy Stock, MD

Blood (2004) 104 (11): 1652.

https://doi.org/10.1182/blood.V104.11.1652.1652

Published: 2004

NARROW

Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?,

Early Interim FDG-PET Scan Predicts Outcome in Non-Bulky Limited Stage Hodgkin Lymphoma, but may Not Guide Use of Consolidative Radiotherapy.

Chemotherapy Alone for Localized Non-Bulky Hodgkin Lymphoma

Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results.

Non-Myeloablative Allogeneic Transplantation for Hodgkin’s and Non-Hodgkin’s Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism.

Immuno-Chemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909.

CALGB 59901: Results of a Phase II Study of 506U78 in CTCL and PTCL.

Sequential Topoisomerase I (Topo I) and Topoisomerase II (Topo II) Inhibitors in Relapsed/Refractory Aggressive NHL: Results of CALGN 59906, a Phase II Study of Doxorubicin and Topotecan.

Eradication of Minimal Residual Disease during Treatment of Mantle Cell Lymphoma: CALGB 59909.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only